The main findings of our work were that high BSI was highly significantly associated with an improvement of both DFS and OS by multivariate analysis in 188 stage III colon carcinoma patients who had received cytotoxic therapy, whereas presence or absence of Bcl-2 or p53 expression alone was significantly correlated with clinical outcome. This evidence concerns the gene BCL2 and colon carcinoma.